Dr Reddy's Revlimid generic launch tail providing residual cash flows, but the next big-product overhang (Stelara biosimilar) is execution-heavy with crowded competition. India domestic franchise stable. Russia exposure (~5%) remains a tail risk. Valuation reasonable but lacking clear catalysts beyond Stelara ramp.
Thesis reviewed May 29, 2026
Dr Reddy's Laboratories Ltd is headquartered in India, which is currently showing moderate signals.
🇮🇳India54EARLYView India risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 50 | +8% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | ↓0% | AVOID |
| SNY | Sanofi | 50 | +14% | ↓0% | EARLY |
| RDY | Dr Reddy's Laboratories Ltd | 50 | +7% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
Investors who hold RDY may also have indirect exposure through these country funds.
Dr Reddy's launches Stelara biosimilar in US; pricing aggressive vs Amgen
Revlimid generic revenue contribution declines as expected
GLP-1 generic pipeline progressing; Semaglutide Brazil first commercial launch
Estimates · Yahoo Finance · Not audited figures